# Excelsior Sciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/excelsior-sciences

- Industry: Biotechnology
- Headquarters: New York, US
- Website: www.excelsiorsci.com/
- Total disclosed funding: $70M
- Latest round: Series A (Dec 3, 2025)
- Investors on record: 7

## About

Excelsior Sciences, based in the US, specializes in AI-powered solutions for small-molecule chemistry, enhancing automation and accessibility in the synthesis process for various sectors including pharmaceuticals and materials science.Excelsior Sciences focuses on innovative solutions in small-molecule chemistry. The company was founded in New York, US, and has not undergone significant pivots in its business strategy. The latest funding round occurred on December 3, 2025, where Excelsior raised USD 70.00 mn in Series A funding co-led by Deerfield Management, Khosla Ventures, and Sofinnova Partners, with participation from other notable investors. The founder's background and previous ventures remain unspecified.Excelsior Sciences develops innovative small-molecule solutions through its proprietary smart blocc platform, which revolutionizes the traditional chemistry synthesis process by making it accessible to automation, artificial intelligence, and non-specialists. The company's primary offerings focus on modular, machine-ready chemical building blocks, enabling rapid carbon-carbon bond formation. These products address critical challenges in the pharmaceutical, materials science, and agricultural technology sectors, facilitating the discovery and manufacturing of new medicines and materials at unprecedented speeds. Excelsior’s technology allows for seamless scaling from milligram to kilogram production, thereby enhancing supply chain resilience and enabling reshoring initiatives, serving a diverse client base across North America and Europe.Excelsior Sciences has secured significant funding, including USD 70.00 mn from its Series A financing round and a USD 25.00 mn grant from New York’s Empire State Development. Revenue primarily stems from partnerships with pharmaceutical and materials science companies, utilizing smart bloccs in small-molecule discovery and manufacturing, generating transactional revenue through B2B engagements. The pricing structure is based on the applications of the smart blocc platform and production scale, aiming for tailored solutions that meet various industry needs.In December 2025, Excelsior Sciences raised USD 70.00 mn in Series A funding to scale its smart bloccs platform, accelerate small molecule discovery and manufacturing, and invest in its pipeline. The company plans to expand its market presence by building partnerships across therapeutics and materials science while supporting reshoring initiatives. The recent funding will facilitate these expansions, aligning with the company’s strategic goals for growth in both existing and new markets.

## Funding rounds

- Series A, Dec 3, 2025, $70M — Sofinnova Partners, Illinois Ventures, Khosla Ventures, Eli Lilly & Company, Deerfield Management, Massachusetts Institute of Technology, Cornucopian Capital

## Investors

- Sofinnova Partners (https://capitalatlas.ai/funds/sofinnova-partners) — Series A
- Illinois Ventures (https://capitalatlas.ai/funds/illinois-ventures) — Series A
- Khosla Ventures (https://capitalatlas.ai/funds/khosla-ventures) — Series A
- Eli Lilly & Company — Series A
- Deerfield Management (https://capitalatlas.ai/funds/deerfield-management) — Series A
- Massachusetts Institute of Technology — Series A
- Cornucopian Capital (https://capitalatlas.ai/funds/cornucopian-capital) — Series A